, Tracking Stock Market Picks
Enter Symbol:
Biogen Idec Inc (BIIB) [hlAlert]

up 62.38 %

Biogen Idec Inc (BIIB) rated Buy with price target $376 by Stifel

Posted on: Tuesday,  Aug 19, 2014  12:00 AM ET by Stifel

Stifel rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 08/19/2014. Previously Stifel rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 03/28/2013.,
when the stock price was $187.51. Since then, Biogen Idec Inc has gained 62.39% as of 01/07/2016's recent price of $304.49.
If you would have followed the previous Stifel's recommendation on BIIB, you would have gained 62.38% of your investment in 1015 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/19/2014 12:00 AM Buy
345.84 376.00
as of 10/17/2014
1 Week down  -2.67 %
1 Month down  -6.37 %
3 Months up  2.47 %
1 YTD up  9.70 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/19/2014 8:25 AM Buy
350.01 376.00
3/3/2014 9:25 AM Buy
338.38 360.00
1/16/2014 8:25 AM Buy
294.00 321.00
1/16/2014 8:25 AM Buy
294.00 321.00
3/28/2013 8:25 AM Buy
187.51 202.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy